Cost-effectiveness of a routine varicella vaccination program for US children.
about
Vaccination greatly reduces disease, disability, death and inequity worldwideVaricella-zoster virusReview of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project dataVaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project dataThe business case for quality: combining medical literature research with health plan data to establish value for nonclinical managers.Preventing varicella-zoster diseaseIssues in studying the effectiveness of health services for childrenVaricella vaccination in England and Wales: cost-utility analysis.Varicella vaccination--a critical review of the evidence.Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Too much of a good thing? When to stop catch-up vaccinationAssessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and MedicineComplications of varicella in a defined central European population.Vaccination to prevent varicella and shingles.Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel.The role of funding and policies on innovation in cancer drug development.Varicella zoster virus infections in Canadian children in the prevaccine era: A hospital-based studySystematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Effectiveness of live varicella vaccine.Reactogenicity to a live attenuated varicella vaccine in Canadian childrenVaricella susceptibility in a Canadian population.Burden of chickenpox on families: A study in Quebec.Successes and remaining challenges after 10 years of varicella vaccination in the USA.Fostering partnerships for vaccine development: a delicate fabricCost-effectiveness of varicella vaccination programs: an update of the literature.Mass vaccination to control chickenpox: the influence of zoster.Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe.Are economic evaluations an important tool in vaccine policy decisions?Three-year follow-up of protection rates in children given varicella vaccine.New and improved vaccines. Promising weapons against varicella, hepatitis A, and typhoid fever.Increased large unstained cells value in varicella patients: A valuable parameter to aid rapid diagnosis of varicella infection.Immunisation against chickenpox.Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price?Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong.Varicella-zoster virus infection in Australia.The case against universal varicella vaccination.Varicella and herpes zoster vaccine development: lessons learned.Vaccination update.
P2860
Q24648884-A9CECD5A-C557-4CD7-B396-A2B80312AB32Q24683811-40A36AB0-0C13-4A49-9A02-0D3F86A9B979Q26863614-11058237-3396-43CB-A16E-6E2CE97D1471Q30701352-403B6E9A-F175-4052-8989-CF96602A343AQ33202419-0279DDAC-C1E6-4C68-B0B7-B18FF3A4BC40Q33719386-689E6548-9441-443F-AB3B-21FE264755A5Q33726499-49B756D8-F5AB-4450-995B-A1BE00AB11F1Q34263829-3F1C6645-1B49-419D-90AB-0DC924CBCC03Q34315355-5349D7C2-77A0-4B2B-83F5-E11F536F9516Q34578813-7BAB4FEE-8B99-4E5C-A479-ACA436EE2249Q34585496-228D923A-AB50-4425-9F18-9695E47B6534Q34753553-E25CE76B-CC23-4B26-A233-796F6D833D65Q35261530-DF7EA6CC-0591-4D67-960F-628F31A0AC1DQ35397475-2DEF5B73-7C16-4350-8A8D-4F75C661FCF1Q35571925-AC3DE496-3ADE-4E83-800A-3CA14E1FEA05Q35602147-9903C0E4-0BB4-4EFA-BBC1-6DE34C2861A2Q35650184-363B242D-7CDD-42F9-AB21-EAB6CC795D2AQ35652212-AE6FCF09-EEF8-4E91-B4D8-A6B93BCEB746Q35681513-44358EBD-125B-4BB7-AECA-E0B47A6F9382Q36170149-E68939F2-1FD0-4F26-9404-9FC51295E64FQ36170218-EE1B97DE-5A53-4E04-9B2A-79A3ADD86E11Q36170263-CA892412-4CCB-4613-8926-CF71E9971B9FQ36445564-6256EF51-DBF2-47DA-AEBF-5B98D6378726Q36607938-E6476CB1-D2B5-48DE-88C4-028BBA0A4795Q37229923-EA198870-07EC-42CF-AFDD-50B89F5FE10BQ37496233-B3F35DE4-5584-4DCC-8DAE-50EC07F1D8FBQ37660930-244A8D0E-ED22-43EE-B8B5-270DE177577DQ37763127-02FE9EBF-44EE-4998-9F91-D11EF15C0804Q37940554-717CAE60-422E-40D0-8D59-B6B3213D7283Q39827157-8EA51E9B-D4F9-49BB-A2DD-30D5C41D5F6DQ40663377-D799EDAF-2638-4F12-9A90-475F832308A5Q41008755-CE566B5E-86E3-4CC3-BC70-C6020888F1CAQ42556876-700898C0-54F3-49B4-AA35-A45D095E2E4BQ44388059-C0724FD9-ABB6-43EE-AB07-B6C786DF2E22Q44930328-C888D21C-D4EF-44C8-8149-F3872C8B1722Q45186105-B59E1363-83AD-4572-990E-5E9E8CB6170EQ45754928-9D76AA39-6903-4629-B4C0-0796E9E0C245Q46988238-97E911B5-837B-46BF-A523-4A75135A0BBFQ47607699-AD632B7B-DE65-417E-8CC3-9AAA677A98E0Q49967161-D46F236A-F991-47AA-9E14-B31B6729F08F
P2860
Cost-effectiveness of a routine varicella vaccination program for US children.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Cost-effectiveness of a routine varicella vaccination program for US children.
@en
Cost-effectiveness of a routine varicella vaccination program for US children.
@nl
type
label
Cost-effectiveness of a routine varicella vaccination program for US children.
@en
Cost-effectiveness of a routine varicella vaccination program for US children.
@nl
prefLabel
Cost-effectiveness of a routine varicella vaccination program for US children.
@en
Cost-effectiveness of a routine varicella vaccination program for US children.
@nl
P2093
P1476
Cost-effectiveness of a routine varicella vaccination program for US children.
@en
P2093
A E Washington
H R Shinefield
S J Holmes
P304
P356
10.1001/JAMA.1994.03510290057037
P407
P50
P577
1994-02-01T00:00:00Z